Cipher Pharmaceuticals (OTCMKTS:CPHRF) Earns Buy Rating from Echelon Wealth Partners

Cipher Pharmaceuticals (OTCMKTS:CPHRF) (TSE:CPH)‘s stock had its “buy” rating restated by stock analysts at Echelon Wealth Partners in a report issued on Tuesday, reports. They currently have a $4.00 price objective on the stock. Echelon Wealth Partners’ price objective points to a potential upside of 352.44% from the company’s previous close.

Shares of OTCMKTS CPHRF traded down $0.08 during mid-day trading on Tuesday, hitting $0.88. The company had a trading volume of 1,000 shares, compared to its average volume of 4,337. The business’s 50-day simple moving average is $0.99 and its 200 day simple moving average is $0.96. Cipher Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $1.66.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients.

Recommended Story: What is range trading?

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with's FREE daily email newsletter.